CH IDMP (R5)
1.0.0-ballot - ballot
This page is part of the CH IDMP (v1.0.0-ballot: DSTU 1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. This is the current published version. For a full list of available versions, see the Directory of published versions
Profile: MedicinalProductDefinition
CH SMC - Authorized Dose Form: Film-coated tablet
identifier: Medical Product Identifier/CH-01100869-0672110010000
indication:
Xospata wird angewendet für die Behandlung von erwachsenen Patienten, die an rezidivierter oder refraktärer akuter myeloider Leukämie (AML) mit FMS-ähnlichen Tyrosinkinase 3 (FLT3)-Mutationen leiden.
legalStatusOfSupply: A: Single dispensing requiring a medical or veterinary prescription
additionalMonitoringIndicator: No Warning
pediatricUseIndicator: Not authorised for the treatment in children
classification: gilteritinib, Synthetic
| Country | Status | DateRange |
| Switzerland | No interruption of distribution reported | 2020-09-24 --> (ongoing) |
attachedDocument:
name
productName: Xospata 40 mg, Filmtabletten
Usages
Country Language Switzerland German (Switzerland)